(Reuters) – Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly’s blood test as an aid in the initial assessment for Alzheimer’s disease.

This comes at the heel of FDA’s nod for Fujirebio Diagnostics’ blood test Lumipulse in May, the first such device to get approval to diagnose the brain-wasting condition. (Read More)